Ascentage Pharma Group Internat (AAPG) Stock Price & Analysis
Ascentage Pharma Group Internat (AAPG) closed at USD 14.69 on Thursday, October 15, 2026, down 1.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 14.85; the Oct 15, 2026 session ranged USD 14.47–14.93 on volume of 8,874 shares. Market capitalization is $1.37B, with a 52-week range of USD 14.46–35.86 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AAPG.md
Key facts (AAPG)
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 44.5 (range 33–55).
- Total return with dividends: 1Y -59.7% vs S&P 500 +18.1%; 5Y -15.5% vs S&P 500 +85.1%.
- Next earnings: 2026-08-19, EPS estimate USD -0.56, revenue estimate $178M.
Analysts (AAPG)
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 44.5 (low 33, high 55).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Citigroup | Initiated | Buy | $46 |
| 2026-10-13 | Citizens | Initiated | Market Outperform | $35 |
| 2026-10-08 | JP Morgan | Target lowered | Overweight | $46 → $33 |
| 2026-08-21 | BTIG | Reiterated | Buy | $48 |
Total return (dividends reinvested) (AAPG)
| 1Y (from 2025-10-16) | 5Y (from 2025-01-20) | |
|---|---|---|
| Total return | -59.7% | -15.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -59.8% | -9.2% |
| Volatility (annualized) | 59.0% | 64.7% |
| Max drawdown | -60.1% (Oct 2025→Oct 2026) | -69.3% (Aug 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 14.69 |
|---|---|
| Change | ▼ 1.08% (down) |
| Previous Close | USD 14.85 |
| Open | USD 14.47 |
| Day Range | USD 14.47 – 14.93 |
| 52-Week Range | USD 14.46 – 35.86 |
| Volume | 8,874 shares |
| Market Cap | $1.37B |
| Exchange | NGM |
Technical Analysis (AAPG)
Nexqual's technical model rates AAPG "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.59 (neutral) |
| vs SMA50 | Below (USD 16.56) |
| MACD | -0.46 (negative) |
Analyst Ratings (AAPG)
Wall Street analysts rate AAPG "Buy" based on 10 analysts, with a mean price target of USD 44.5 (range USD 33–55), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 44.5 |
| High Target | USD 55 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (AAPG)
| Next Earnings Date | 2026-08-19 |
|---|---|
| EPS Estimate | USD -0.56 |
| Revenue Estimate | $178.31M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (AAPG)
| Total Revenue | $642.64M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +29.30% |
| Gross Margin | +93.93% |
| Operating Margin | -248.91% |
| Profit Margin | -228.54% |
| ROE | -236.63% |
| Debt / Equity | 3.7 |
| Current Ratio | 1.22 |
| Total Cash | $1.90B |
| Total Debt | $2.09B |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (AAPG)
Nexqual rates Ascentage Pharma Group Internat's overall financial health "Critical" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -41% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — CNY 1.90B cash vs CNY 2.09B debt |
| Cash Flow | Weak — Operating cash flow -CNY 1.32B (TTM) |
| Efficiency | Critical — ROE -237%, ROA -28.0% |
Ownership (AAPG)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.04% |
| Shares Outstanding | 93.39M |
| Float | 71.53M |
| Short % of Float | +0.01% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (AAPG)
Ascentage Pharma Group Internat is led by Dajun Yang (age 62), Co-Founder, Chairman & CEO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, Chairman & CEO | Dajun Yang (age 62) |
|---|---|
| Co-Founder, Chief Scientific Advisor & Non-Executive Director | Shaomeng Wang (age 60) |
| Chief Financial Officer | Veet Misra |
| Senior Director of Investor Relations | Yuly Chen |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt